Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia.
Moles E, Howard CB, Huda P, Karsa M, McCalmont H, Kimpton K, Duly A, Chen Y, Huang Y, Tursky ML, Ma D, Bustamante S, Pickford R, Connerty P, Omari S, Jolly CJ, Joshi S, Shen S, Pimanda JE, Dolnikov A, Cheung LC, Kotecha RS, Norris MD, Haber M, de Bock CE, Somers K, Lock RB, Thurecht KJ, Kavallaris M.
Moles E, et al. Among authors: pickford r.
Sci Transl Med. 2023 May 17;15(696):eabm1262. doi: 10.1126/scitranslmed.abm1262. Epub 2023 May 17.
Sci Transl Med. 2023.
PMID: 37196067